Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A retrospective analysis from The Australasian Bone Marrow Transplant Recipient Registry.

[1]  N. Kröger,et al.  Survival following allogeneic transplant in patients with myelofibrosis. , 2020, Blood advances.

[2]  N. Kröger,et al.  Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  M. Heuser,et al.  Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. , 2019, Blood.

[4]  M. Robin,et al.  State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 , 2019, Haematologica.

[5]  H. Einsele,et al.  Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis , 2019, Haematologica.

[6]  J. Bourhis,et al.  Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis , 2019, Haematologica.

[7]  G. Helbig,et al.  Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis , 2019, Medical Oncology.

[8]  P. Guglielmelli,et al.  MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Lancet,et al.  Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation , 2018, Annals of Hematology.

[11]  H. Kantarjian,et al.  Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. , 2017, Blood.

[12]  M. Heuser,et al.  Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  P. Chevallier,et al.  Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? , 2017, European journal of haematology.

[14]  R. Mesa,et al.  Transplantation in Myelofibrosis Reaches the Molecular Age. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  S. Chevret,et al.  The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  T Giorgino,et al.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.

[17]  V. Najfeld,et al.  Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  E. Holler,et al.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation , 2016, Haematologica.

[19]  Giuseppe Milone,et al.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.

[20]  M. Griesshammer,et al.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group , 2015, Leukemia.

[21]  M. MacMillan,et al.  Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.

[22]  M. Cazzola,et al.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. , 2014, Blood.

[23]  V. Najfeld,et al.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. , 2014, Blood.

[24]  M. Cazzola,et al.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.

[25]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[26]  G. Barosi.  Emerging targeted therapies in myelofibrosis , 2012, Expert review of hematology.

[27]  H. Deeg,et al.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. , 2012, Blood.

[28]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[29]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[30]  J. Simpson,et al.  Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  R. Porcher,et al.  Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis , 2011, Bone Marrow Transplantation.

[32]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[34]  H. Einsele,et al.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[35]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[36]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[37]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[38]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[39]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[40]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[41]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.